Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
Sponsor: Ehab L Atallah
Terminated
SAE- risk of overall protocol treatment outweighs benefits
Other terminated trials from Ehab L Atallah
More terminations from Ehab L Atallah
Listed as NCT01887587, this PHASE1 trial focuses on Mixed Phenotype Acute Leukemia and Relapsed or Refractory Acute Lymphoblastic Leukemia and remains terminated or withdrawn. Sponsored by Ehab L Atallah, it has been updated 9 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE1
▶ Show 4 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Feb 2020 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ehab L Atallah
For direct contact, visit the study record on ClinicalTrials.gov .